Martin Williams
Senior Research Fellow at the Centre for Mental Health, Swinburne University; Adjunct in Computational Neuroscience at the Turner Institute, Monash University; Executive Director of Psychedelic Research in Science & Medicine (PRISM)
Data updated
Research Footprint
Martin Williams appears in 6 tracked papers (2020–2025), most studied alongside Psilocybin, Ayahuasca and LSD, across Depressive Disorders, Eating Disorders and Anxiety Disorders.
Most-cited paper: Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications (47 citations).
Frequent co-authors: Adele Lafrance, Kyle Greenway and Paul Liknaitzky.
Background & Research
Martin Williams, PhD, is an Australian researcher focused on psychedelic-assisted psychotherapy and the neuroscience and clinical application of psychedelics. He has co-authored papers on psilocybin treatment for depression, music in psychedelic therapy, and broader psychedelic science, and has helped lead research initiatives through PRISM and academic institutions in Melbourne. He is also active in public-facing education and policy work around psychedelic medicine in Australia.
Key Impact
He is a prominent Australian psychedelic researcher and advocate whose work spans psychedelic-assisted psychotherapy, clinical trials, and the science of music and context in psychedelic therapy.
Collaboration Network
14 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Martin Williams is associated with.
Swinburne University
Swinburne University of Technology is a public university based in Melbourne, Australia, known for its focus on technology, industry partnerships, and applied research. It operates multiple campuses (including Hawthorn and an international campus in Sarawak, Malaysia) and offers on-campus and online study options.
View stakeholder →Monash University
academicThe Clinical Psychedelic Lab, led by Dr. Paul Liknaitzky, conducts robust clinical trials exploring the efficacy and safety of psychedelic-assisted therapies for various mental health conditions within the Australian healthcare context.
View stakeholder →Psychedelic Research in Science & Medicine (PRISM)
Psychedelic Research in Science & Medicine (PRISM) is an Australian nonprofit research charity based in Melbourne, with activity and collaborators across Australia and internationally. It was established in 2011 to initiate, coordinate, and support formal research into medicinal psychedelics and related technologies. PRISM says it serves researchers, clinicians, and the wider psychedelic science community through scientific expertise, education, and consultation. PRISM’s public role is centered on evidence-based psychedelic science, knowledge translation, and policy-facing advocacy rather than direct patient services. Its website describes a research network that connects academics, clinicians, and students to coordinate study proposals, collaborations, funding opportunities, and peer-to-peer education. Documented current initiatives include a Psychedelic Research Network and support for Australian clinical research, including work related to psilocybin, MDMA, and virtual reality tools for preparation and integration.
View stakeholder →